nach oben

Erschienen in:

06.06.2023 | Research

Tissue and plasma free amino acid detection by LC-MS/MS method in high grade glioma patients

verfasst von: Sureyya Toklu, Rahsan Kemerdere, Tibet Kacira, Murat Serdar Gurses, Fehime Benli Aksungar, Taner Tanriverdi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The changes in serum amino acid profiles are evaluated in different types of cancers and screening tests were developed for estimating the risk of cancer by rapid analysis of plasma free amino acid (PFAA) levels. There is scarce evidence about the metabolomics analysis of PFAA in malignant gliomas. The aim of the present study was to identify the most promising diagnostic amino acid biomarkers that could be objectively measured for high-grade glioma and to compare their level with the tissue counterpart.

Methods

In this prospective study, we collected serum samples from 22 patients with the pathological diagnosis of high-grade diffuse glioma according to WHO 2016 classification and 22 healthy subjects, and brain tissue from 22 controls. Plasma and tissue amino acid concentrations were analyzed applying liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

Results

Serum alanine, alpha-aminobutyric acid (AABA), lysine (Lys) and cysteine concentrations were significantly higher in high-grade glioma patients despite low levels of alanine and Lys in the tumor tissue. Aspartic acid, histidine and taurine were significantly decreased in both serum and tumors of glioma patients. A positive correlation was detected between tumor volumes and serum levels of latter three amino acids.

Conclusion

This study demonstrated potential amino acids which may have diagnostic value for high-grade glioma patients by utilizing LC-MS/MS method. Our results are preliminary to compare serum and tissue levels of amino acids in patients with malignant gliomas. The data presented here may provide feature ideas about the metabolic pathways in the pathogenesis of gliomas.

Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2021) CBTRUS Statistical Report: primary brain and other Central Nervous System Tumors diagnosed in the United States in 2014–2018. Neuro Oncol 23(12 Suppl 2):iii1-iii105. https://doi.org/10.1093/neuonc/noab200.CrossRefPubMedPubMedCentral

Mörén L, Bergenheim AT, Ghasimi S, Brännström T, Johansson M, Antti H (2015) Metabolomic screening of tumour tissue and serum in glioma patients reveals diagnostic and prognostic information. Metabolites 5:502–520. https://doi.org/10.3390/metabo5030502.CrossRefPubMedPubMedCentral

Holdhoff M, Yovino SG, Boadu O, Grossman SA (2013) Blood-based biomarkers for malignant gliomas. J Neurooncol 113:345–352. https://doi.org/10.1007/s11060-013-1144-0.CrossRefPubMedPubMedCentral

Wu G (2009) Amino acids: metabolism, functions, and nutrition. Amino Acids. 37:1–17. https://doi.org/10.1007/s00726-009-0269-0.CrossRefPubMed

Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP (2015) Circulating glioma biomarkers. Neuro Oncol 17:343–360. https://doi.org/10.1093/neuonc/nou207.CrossRefPubMed

Lai HS, Lee JC, Lee PH, Wang ST, Chen WJ (2005) Plasma free amino acid profile in cancer patients. Semin Cancer Biol 15:267–76. https://doi.org/10.1016/j.semcancer.2005.04.003.CrossRefPubMed

Mikami H, Kimura O, Yamamoto H, Kikuchi S, Nakamura Y, Ando T, Yamakado M (2019) A multicentre clinical validation of AminoIndex Cancer Screening (AICS). Sci Rep 9:13831. https://doi.org/10.1038/s41598-019-50304-y.CrossRefPubMedPubMedCentral

Jothi J, Janardhanam VA, Krishnaswamy R (2020) Metabolic variations between Low-Grade and High-Grade Gliomas-Profiling by 1H NMR spectroscopy. J Proteome Res 19:2483–2490. https://doi.org/10.1021/acs.jproteome.0c00243.CrossRefPubMed

Baranovičová E, Galanda T, Galanda M, Hatok J, Kolarovszki B, Richterová R, Račay P (2019) Metabolomic profiling of blood plasma in patients with primary brain tumours: basal plasma metabolites correlated with tumour grade and plasma biomarker analysis predicts feasibility of the successful statistical discrimination from healthy subjects - a preliminary study. IUBMB Life 71:1994–2002. https://doi.org/10.1002/iub.2149.CrossRefPubMed

10.

Bobeff EJ, Szczesna D, Bieńkowski M, Janczar K, Chmielewska-Kassassir M, Wiśniewski K, Papierz W, Wozniak LA, Jaskólski DJ (2021) Plasma amino acids indicate glioblastoma with ATRX loss. Amino Acids 53:119–132. https://doi.org/10.1007/s00726-020-02931-3.CrossRefPubMed

11.

Kelimu A, Xie R, Zhang K, Zhuang Z, Mamtimin B, Sheyhidin I (2016) Metabonomic signature analysis in plasma samples of glioma patients based on (1)H-nuclear magnetic resonance spectroscopy. Neurol India 64:246–51. https://doi.org/10.4103/0028-3886.177606.CrossRefPubMed

12.

Li P and Bartlett MG (2014) A review of sample preparation methods for quantitation of small-molecule analytes in brain tissue by liquid chromatography tandem mass spectrometry (LC-MS/MS). Anal Methods 6:6183–6207. https://doi.org/10.1039/C4AY00915K.CrossRef

13.

D’Agostino RB, Nam BH (2003) Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR (eds) Handbook of Statistics. Elsevier, New York, NY, pp 1–25

14.

Ali H, Harting R, de Vries R, Ali M, Wurdinger T, Best MG (2021) Blood-based biomarkers for glioma in the context of gliomagenesis: a systematic review. Front Oncol 11:665235. https://doi.org/10.3389/fonc.2021.665235.CrossRefPubMedPubMedCentral

15.

Bylda C, Thiele R, Kobold U, Volmer DA (2014) Recent advances in sample preparation techniques to overcome difficulties encountered during quantitative analysis of small molecules from biofluids using LC-MS/MS. Analyst. 21:2265–76. https://doi.org/10.1039/c4an00094c.CrossRef

16.

Pisters PW, Pearlstone DB (1993) Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 30:223–272. https://doi.org/10.3109/10408369309084669.CrossRefPubMed

17.

Jia B, Wang W, Lin S, Shi L, Li Y, Gu Y, Gao F, Qin Y (2020) The free amino acid profiles and metabolic biomarkers of predicting the chemotherapeutic response in advanced sarcoma patients. Clin Transl Oncol 22:2213–2221. https://doi.org/10.1007/s12094-020-02494-5.CrossRefPubMed

18.

Cadoni G, Giraldi L, Chiarla C, Gervasoni J, Persichilli S, Primiano A, Settimi S, Galli J, Paludetti G, Arzani D, Boccia S, Giovannini I, Almadori G (2020) Prognostic role of serum amino acids in Head and Neck Cancer. Dis Markers 2020:2291759. https://doi.org/10.1155/2020/2291759.CrossRefPubMedPubMedCentral

19.

Dols MC, López MD, Plaza CR, Miranda EP, Calle SG, Chamorro EV, Díaz IA, Pino AM, García JA, Calderón VG (2006) Specific alterations in the serum amino acid profile of patients with lung cancer and head and neck cancer. Oncologia 29:283–90. https://doi.org/10.4321/S0378-48352006000700002.CrossRef

20.

Closs EI, Scheld JS, Sharaf M, Forstermann U (2000) Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 57:68–74.PubMed

21.

Rahat MA, Hemmerlein B (2013) Macrophage-tumor cell interactions regulate the function of nitric oxide. Front Physiol 18:144. https://doi.org/10.3389/fphys.2013.00144.CrossRef

22.

Mörén L, Wibom C, Bergström P, Johansson M, Antti H, Bergenheim AT (2016) Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas. Radiat Oncol 11:51. https://doi.org/10.1186/s13014-016-0626-6.CrossRefPubMedPubMedCentral

23.

Kubota A, Meguid MM, Hitch DC (1992) Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 69:2343–8. https://doi.org/10.1002/1097-0142(19920501)69:9<2343::aid-cncr2820690924>3.0.co;2-s.CrossRefPubMed

24.

Zhang HF, Klein Geltink RI, Parker SJ, Sorensen PH (2022) Transsulfuration, minor player or crucial for cysteine homeostasis in cancer. Trends Cell Biol 32:800–814. https://doi.org/10.1016/j.tcb.2022.02.009.CrossRefPubMed

25.

Shanker G, Allen JW, Mutkus LA, Aschner M (2001) The uptake of cysteine in cultured primary astrocytes and neurons. Brain research 902:156–163. https://doi.org/10.1016/s0006-8993(01)02342-3.CrossRefPubMed

26.

Prabhu A, Sarcar B, Kahali S, Yuan Z, Johnson JJ, Adam KP, Kensicki E, Chinnaiyan P (2014) Cysteine catabolism: a novel metabolic pathway contributing to glioblastoma growth. Cancer research 74:787–796. https://doi.org/10.1158/0008-5472.CAN-13-1423.CrossRefPubMed

27.

Cuperlovic-Culf M, Ferguson D, Culf A, Morin P, Touaibia M (2012) 1H NMR metabolomics analysis of glioblastoma subtypes correlation between metabolomics and gene expression characteristics. Journal of Biological Chemistry 287:20164–20175. https://doi.org/10.1074/jbc.M111.337196.CrossRefPubMedPubMedCentral

28.

Westergren I, Nyström B, Hamberger A, Nordborg C, Johansson BB (1994) Concentrations of amino acids in extracellular fuid after opening of the blood-brain barrier by intracarotid infusion of protamine sulfate. J Neurochem 62:159–165. https://doi.org/10.1046/j.1471-4159.1994.62010159.x.CrossRefPubMed

29.

Suh EH, Hackett EP, Wynn RM, Chuang DT, Zhang B, Luo W, Sherry AD, Park JM (2019) In vivo assessment of increased oxidation of branched-chain amino acids in glioblastoma. Sci Rep 9:340. https://doi.org/10.1038/s41598-018-37390-0.CrossRefPubMedPubMedCentral

30.

Lopez-lopez A, Lopeez-Gonzalvez A, Barker-Tejeda TC, Barbas C (2018) A review of validated biomarkers obtained through metabolomics. Expert Rew Mol Diagn. 18:557–575. https://doi.org/10.1080/14737159.2018.1481391.CrossRef

Titel: Tissue and plasma free amino acid detection by LC-MS/MS method in high grade glioma patients
verfasst von: Sureyya Toklu
Rahsan Kemerdere
Tibet Kacira
Murat Serdar Gurses
Fehime Benli Aksungar
Taner Tanriverdi
Publikationsdatum: 06.06.2023
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2023
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04329-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Safety and efficacy of Cesium-131 brachytherapy for brain tumors

Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas

Conceptual development of an intensive exercise program for glioma patients (ActiNO): summary of clinical experience

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status

A novel prognostic model based on pretreatment serum albumin and ECOG PS for primary CNS lymphoma: an international, multi-center study